Literature DB >> 1716263

Intravenous gamma-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies.

R Liblau1, P Gajdos, F A Bustarret, R el Habib, J F Bach, E Morel.   

Abstract

Clinical improvement has been observed in myasthenia gravis patients treated by intravenous immunoglobulin (IVIg). In order to investigate the mechanism of action of these IVIg, we looked for an in vitro interaction between IVIg and the anti-acetylcholine receptor autoantibodies. Significant inhibition by IVIg of anti-acetylcholine receptor autoantibody activity from 30 MG sera was observed and binding of anti-acetylcholine receptor autoantibodies on IVIg was found for four of five myasthenia gravis sera. These observations suggest that IVIg contains Ig directly binding to and inhibiting pathogenic autoantibodies.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1716263     DOI： 10.1007/bf00918680

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN： 0271-9142            Impact factor:   8.317


  12 in total

1.  Bullous pemphigoid and intravenous gammaglobulin.

Authors:  W Godard; J C Roujeau; B Guillot; C Andre; G Rifle
Journal:  Ann Intern Med       Date:  1985-12       Impact factor: 25.391

2.  Treatment of antibody-mediated pure red-cell aplasia with high-dose intravenous gamma globulin.

Authors:  W A McGuire; H H Yang; E Bruno; J Brandt; R Briddell; T D Coates; R Hoffman
Journal:  N Engl J Med       Date:  1987-10-15       Impact factor: 91.245

Review 3.  Theoretical mechanisms by which immunoglobulin therapy might benefit myasthenia gravis.

Authors:  B Zweiman
Journal:  Clin Immunol Immunopathol       Date:  1989-11

4.  High-dose intravenous immunoglobulin in the management of myasthenia gravis.

Authors:  E L Arsura; A Bick; N G Brunner; T Namba; D Grob
Journal:  Arch Intern Med       Date:  1986-07

5.  Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin.

Authors:  Y Sultan; M D Kazatchkine; P Maisonneuve; U E Nydegger
Journal:  Lancet       Date:  1984-10-06       Impact factor: 79.321

6.  Immediate effects of intravenous IgG administration on peripheral blood B and T cells and polymorphonuclear cells in patients with myasthenia gravis.

Authors:  L Cook; J F Howard; J D Folds
Journal:  J Clin Immunol       Date:  1988-01       Impact factor: 8.317

7.  High-dose intravenous gammaglobulin for myasthenia gravis.

Authors:  A Fateh-Moghadam; M Wick; U Besinger; R G Geursen
Journal:  Lancet       Date:  1984-04-14       Impact factor: 79.321

8.  High-dose intravenous gammaglobulin for myasthenia gravis.

Authors:  P Gajdos; H Outin; D Elkharrat; D Brunel; P de Rohan-Chabot; J C Raphael; M Goulon; C Goulon-Goeau; E Morel
Journal:  Lancet       Date:  1984-02-18       Impact factor: 79.321

9.  Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin.

Authors:  J Fehr; V Hofmann; U Kappeler
Journal:  N Engl J Med       Date:  1982-05-27       Impact factor: 91.245

10.  Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins.

Authors:  F Rossi; Y Sultan; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330
View more
  13 in total

Review 1.  Protective role of anti-idiotypic antibodies in autoimmunity--lessons for type 1 diabetes.

Authors:  Christiane S Hampe
Journal:  Autoimmunity       Date:  2012-02-23       Impact factor: 2.815

Review 2.  Facing the enigma of immunomodulatory effects of intravenous immunoglobulin.

Authors:  Tal Sapir; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 3.  Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

Authors:  Vir-Singh Negi; Sriramulu Elluru; Sophie Sibéril; Stéphanie Graff-Dubois; Luc Mouthon; Michel D Kazatchkine; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2007-03-11       Impact factor: 8.317

4.  Variability of the inhibition by total immunoglobulin of in vitro autoantibody-mediated erythrophagocytosis by mouse macrophages.

Authors:  S Léonard; I Pierard; T E Michaelsen; S Izui; P L Masson; J-P Coutelier
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

5.  Anti-idiotypic antibodies prevent the serologic detection of antiribosomal P autoantibodies in healthy adults.

Authors:  Z J Pan; C J Anderson; H A Stafford
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

Review 6.  Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease.

Authors:  Adam Quick; Rup Tandan
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.592

7.  Poliomyelitis-like syndrome following asthmatic attack (Hopkins' syndrome)--recovery associated with i.v. gamma globulin treatment.

Authors:  H A Cohen; A Ashkenasi; H Ring; R Weiss; B Wolach; G Paret; A Barzilai
Journal:  Infection       Date:  1998 Jul-Aug       Impact factor: 3.553

Review 8.  Intravenous immune globulin in myasthenia gravis.

Authors:  P Gajdos
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

9.  Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin.

Authors:  C Richter; A Schnabel; E Csernok; K De Groot; E Reinhold-Keller; W L Gross
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

10.  Antiidiotype antibody against platelet anti-GPIIIa contributes to the regulation of thrombocytopenia in HIV-1-ITP patients.

Authors:  M Nardi; S Karpatkin
Journal:  J Exp Med       Date:  2000-06-19       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.